BioCardia, Inc.: Form 10-Q for the period ended Mar 31, 2012
Filed with the SEC on May 15, 2012 and accepted by EDGAR at May 15, 2012, 09:55 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-01-01 to 2012-03-31 | $11.0k | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2012-01-01 to 2012-03-31 | $0 | us-gaap:CostOfRevenue |
| Gross profit | 3 months2012-01-01 to 2012-03-31 | $11.0k | us-gaap:GrossProfit |
| Operating income | 3 months2012-01-01 to 2012-03-31 | −$58.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2012-01-01 to 2012-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-01-01 to 2012-03-31 | −$55.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2012-01-01 to 2012-03-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months2012-01-01 to 2012-03-31 | 230,293,141 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2012-01-01 to 2012-03-31 | −$26.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2012-01-01 to 2012-03-31 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-03-31 | $12.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Total assets | At period end2012-03-31 | $13.6m | us-gaap:Assets |
| Total liabilities | At period end2012-03-31 | $711.0k | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-03-31 | $12.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001136261-12-000295. Last ingested by Listed: Nov 13, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.